Live Stream Review: Philly Music Fest Day One Featuring Japanese Breakfast, The Districts, and More – mxdwn.com

Paige Strickland October 1st, 2020 - 1:06 PM

Philadelphias hottest up and coming bands form the lineup of Philly Music Fest, taking place this weekend, and live streamed for all to view at no cost. Founded, produced and curated by Greg Seltzer, the non-profit events mission is to showcase the ever-expanding local music scene in Philadelphia while raising funds for local music education programs. Day one was a culmination of a diverse group of musicians that brought something distinctive to the experience.

Arnetta Johnson & SUNNY launched the night into full swing. Johnson picked up the trumpet at age 13 and has since played alongside Beyonc, Solange, Janelle Mone and more. Her relationship with the trumpet is a sweet one. Taking front stage, as she closed her eyes and pursed her lips, smooth notes poured out the end of her horn in an effortless fashion. Joined by an ensemble of equally talented supporting trumpets, saxophone, drums, bass and keyboards, the group generated a calamity of rich overlapping layers in sound.

Arnetta Johnson & SUNNY released the album If you Hear a Trumpet Its Me last year, and during their set listeners got a taste of several of its tracks such as Who Are You. A modern choice of production molded together seamlessly with their classic elements of jazz. The group was excited to be back in front of a live audience after a long lull during COVID-19 shutdowns, and the energy was both genuine and uplifting.

Formed in 2009 during their high school years, The Districts have grown to be a popular indie rock band known by NME Magazine as The Band Who Owned SXSW. Their sound, laced with hints of blues and rock themes, is one to be savored. The band was thrilled to be back for their first show subsequent to the release of their ironically titled album,You Know Im Not Going Anywhere, which was unveiled right as quarantine started in March. Opening up with the haunting song filled with distortions, electronic sounds and strings, My Only Ghost, Pat Cassidy harmonized wonderfully with lead vocalist Rob Grote.

Going full force for If Before I Wake, heavy bass and sliding guitar chords carried the track as Grote jumped up and down shouting the lyrics, full of energy. The way Grote thrashes his head and body, people have got to think hell be icing it later. For a slight cool down, And The Horses All Go Swimming and 4th of July showed the softer side to The Districts, although the first left room for a skillful breakdown.

The camera zoomed in on a small lamp with HUMAN written in red. A man of charisma who cant be categorized, Zeek Burse stepped on to the scene in glittery cardigan and pants, jewels dangling from his neck and ears. Eyes closed and arms wide open, it was as if he was gently inviting his voice to pour out. His jumping lyrics and range in vocals fluctuated with ease on Dry. Making use of the stage, he danced barefoot and scat sang, beautifully improvising melodies during Summer Vibes. Introducing Dirty Bath Water, Burse explained, while chuckling, Its about someone who left you with the leftovers, right? Weve all been there.

Burse possesses the incredible quality of being able to skip between jazz, blues, R&B and rock all in one set. He quoted Nina Simone: How can I be an artist and not reflect the times? while adding This is us reflecting the times as well as the future. In a 60s-esque Black Lives Matter song, the guitarist shredded scales as Burse chanted black lives matter into the microphone, headbanging, and playing air guitar alongside him, ending with a fist in the air.

If you know one thing about me its that I stand for equality and unity said Burse. This song One People is about balance. Usually during a show like today, I usually ask the audience to put up one finger when we get to the hook. Only put it up if you believe it right? Its like church, dont do it if you dont believe it. But its basically just saying we are one people. No matter where youre from, who you love, what you look like, we are one people and we can change the world. The track was a refreshing, inspiring ballad among his high energy set.

Japanese Breakfast is glad to be back as well. It feels so great to play together again, this is our first show that weve played together all year, and it feels really really special, said lead singer Michelle Zaunder. The indie rock artist kicked off her set with Diving Woman, from Soft Sounds From Another Planet, followed by In Heaven, from her first studio album Psychopomp.

Zauner set down her guitar for her beloved top track Road Head. Close ups revealed Zauners expressive singing as her face transformed from grins to a scrunched up nose, fighting to hit those falsettos, and leveling them gracefully. Dancing and grooving to her own tracks, it was lovely to see her genuine enjoyment, and viewers on screen jived along with her.

Molly Germer joined the band on violin for a new song that has never been played for a live audience. This song is called Kokomo Indiana, said Zauner. I wrote it from the perspective of a love-lorne, like, 17-year-old boy whose girlfriend moves to Australia in the summer exchange program, because that to me is like the apex of feeling. The lovesick, twangy song was reminiscent of nostalgic youthful moments and begged to have lighters waving in a crowd.

Following their original tracks, the band also performed a couple of heartwarming covers. A spot-on rendition of Tears for Fears Head Over Heels ended in the blissful na na nas and hands waving in the air. Before the set came to a close with a Japanese Breakfast version of The Useds The Taste of Ink, Zauner spoke out on the current state of social injustice.

It would feel remiss if I didnt take every opportunity in which we have a platform to essay that black lives matter, she said. That means not just saying it but fighting for injustice, it means marching in the streets if youre able to. Please vote, it is not by any means the end to all of this, but it is very important and I hope that you will triple-check your registration this week and please go out and vote. March for Breonna Taylor, It is absolutely disgusting what is happening. We must work together to defund the police and invest in our communities.

PhotoCredit: Kalyn Oyer

See original here:

Live Stream Review: Philly Music Fest Day One Featuring Japanese Breakfast, The Districts, and More - mxdwn.com

Arizona Zervas / The Success Of Roxanne & Staying In His Own Lane – Flaunt Magazine

I was listening to FML, do you have a bae?

Somethings been in the works for a while, but keep it on the DL for now.

Do you eventually want to settle down and have kids?

I guess. After a certain point in life, thats the new dream but I wouldnt know. Right now, Im trying to take it one at a time. Trying to create a happy environment for whoever Im around, whether its the girl or my friends. FML is about the same girl, so Im on the right track. Its funny because FML came out before Roxanne. Thats the fear of being around a girl who might be a Roxanne, but you still want to take your shot at it.

I made the song the day after I met her for the first time. She was a bit suspicious. It could be me overthinking it but even still, I wanted to date her off rip which is wild. The day I met her, she picked me up in this new Mercedes, thats how I made the whole song. I hadn't hung out with her for 7 months, I figured I got too drunk and ruined it. I didn't want to push into something, let it happen naturally. We ended up hanging out, this time she came and picked me up in a Nissan. The story is I was super drunk and thought she had a Mercedes, maybe expect a song about a Nissan next. [laughs]

How much of a role did TikTok play in the success of Roxanne?

It's going up. The coolest thing about TikTok is it can be a really positive outlet for kids, an outlet for people to be creative. People are funny, people make music showcasing their talent. Dancing, you can see genuine true fun. Its a lot different from Twitter and Instagram, it could be a facade or even more drama. When Roxanne was bubbling up on TikTok, it seemed fun. It was carefree. Roxanne fit so perfect because I was definitely carefree when I made that. All my best songs are my carefree moments. If Im in the studio not worried about shit, it comes out naturally.

What is your most meaningful tattoo?

Probably this one. [points to forearm] This is my dad, its my little tribute to him. He passed away 10 years ago. I also have this mother/father one, its my second tattoo. [points to other arm] It says mother on one side, father on the other side. Of course, anything family related. I got my mothers handwriting, it says enjoy it.

How proud is she?

Shes hyped. She still calls me every time she hears me on the radio. She has her moments. Shell call me or text me anytime she hears anything Ive done. Its awesome, one of the most important things in life is to keep your mom happy.

What do you want fans to get from your story?

Most important thing for me has always been the DIY of what it takes to make your dreams come to life. You can do anything you want. If you put the right amount of time and effort, stay on your own track and stay focused, anything can truly happen. Its been a really wild journey, always a happy journey too. Its definitely more stressful now but you have to learn and go through these growing pains throughout anything in life, whatever you want to get into. Especially creative because youre not going to always be inspired, its not always going to come so easy.

Any artists you want to work with that you havent yet?

I did one with Swae Lee, hes an awesome guy. I really want to do something with 24kgoldn. Hes up there, hes going crazy right now. I love so many different artists. I always want to meet them first because I know itll be more organic that way.

Goals for yourself at this point?

Always trying to be a better artist, the focal point of my entire life is being a better person. Its always been an obsession to get better at music and be the best me in and outside of the studio. My other goal is making more great songs and more experiences. Going on my first headline tour, thatd be big.

Have you toured?

I toured a bunch of really tiny venues. Coming up, you have to learn the ropes. Those are important times, you learn not everyones going to like your shit so you have to figure out a way to still be entertaining. Maybe they won't like all your shit, but one song.

Its hard to imagine someone would not like your music.

Its tough. Ive heard all types of artists even beyond their success, people with all their plaques are still insecure about their music. Its so weird, Im definitely going through it. Even when I make something great, its more of a moment that you think its so good. As you heard it more and more, you might not have the same feeling you had when you first heard it. The hardest thing about music is staying passionate. I always come back months or a year after its out and be proud of it. It might not hit the same but thats life, just be proud. Especially because I do everything with my friends.

What can we expect music-wise?

Im trying to switch it up. I dont want to do too much of the same thing, thats my biggest fear. Feed the fans fresh stuff. Even if I drop something different, it might not be their favorite but at least its something new. I know some people will love this one, some people wont love that one. Im always trying to sequence them in a different way.

What genre would you call your music?

I have no idea. The world would assume pop, thats what I always say but I started rapping. Not rap rap, more lifestyle rap. Never in your face. Its rap, pop, rock. Personally I like to assume its genreless because I like touching base with everything, but Im sure everyone says that. I don't even think about the genre anymore because you see pop, rap, rock, all being more instrumental now. A lot of guitar, pianos. Its music.

Visit link:

Arizona Zervas / The Success Of Roxanne & Staying In His Own Lane - Flaunt Magazine

Roman Reigns Open To Facing CM Punk: Hed Probably Need To Be Slapped Around A Few Times – Fightful

Roman Reigns is willing to do big business and long-term business depending on what is asked.

Reigns returned to WWE after a five-month hiatus at SummerSlam and immediately reclaimed his spot atop the mountain. Reigns has no shortage of opponents in WWE who make sense and who he could tell stories with, and he's looking to business the right way for the future or the biggest way in the present.

"If I'm asked to build new stars, we need to build my character up a lot more, and that way we can really start diving in to building the future. I'm open to building up the mountain and letting the future climb it," Roman told Complex's Load Management podcast. "If we just want to create headlines and build really good TV, I'm into anybody who can garner that attention. Whether it's someone like Dwayne, if there's anyone to do it and anyone he would feel comfortable with in the ring and have the proper build-up who can rise to that occasion, there's no doubt in my mind that I'm the guy. We're definitely gonna have to crack a lot of eggs on the way to the omelet. That's just good TV. Going forward and building a really dominant bad guy like myself and here comes the astronomical superstar. You have to really build it."

He continued, adding CM Punk to his list of potential top opponents outside of The Rock, "All the way from someone as big as The Rock to someone like a CM Punk. Someone who really hits home with our home audience, our hardcore fans. If you've watched wrestling for the last 10-15 years and it's in your blood, you probably have some kind of feelings about that guy. I know I do. Just by doing one of these things, he made my job a lot harder 5-10 years ago. If it's something the fans can get behind and sink their teeth into the product and dive into the creative with us, I'm willing to do it. I don't like the guy, I don't know many people that do, but I'm willing to put business first and make good content. He'd probably need to be slapped around a few times in order to get his mind right. If the fans are going to like it, most likely I'm going to do it."

Punk left WWE in 2014 in a nasty split that ended up going to trial with WWE doctor Christopher Amann filing a defamation lawsuit against him. Punk began loosely working with WWE as part of WWE Backstage on FOX in November 2019, but has stated many times that he is not actively pursuing a return to wrestling.

However, The Rock seems more than willing to battle Reigns on the big stage at WrestleMania.

If you use any of the quotes above, please give a h/t and link back to Fightful for the transcription.

See the article here:

Roman Reigns Open To Facing CM Punk: Hed Probably Need To Be Slapped Around A Few Times - Fightful

Statue of Liberty-sized space rock among FIVE headed towards Earth warns NASA – RT

In its latest bulletin, NASA has warned of five Near-Earth Objects headed towards our planet this week, one of which is larger than the Statue of Liberty. Meanwhile, the agency is gearing up for its asteroid-sampling mission.

Itll be a ferocious finale to September, as five space rocks measuring between 11 meters and 110 meters in diameter are due in just three days.

Kicking things off on Monday will be the 11-meter, telephone pole-sized 2020 SY4, which will come within 724,000km of Earth at a blistering pace of 16.12km/s (58,032kph, or 21 times as fast as a bullet (2,736kph).

On Tuesday, the behemoth 2020 PM7, which has a diameter of 110 meters, will shoot past at a safe distance of 2.8 million km. The giant rock is equivalent to 30 Volkswagen Beetles end-to-end, or about one-and-one-fifth times as tall as the Statue of Liberty.

To close the show, on September 30, three space rocks will fly by our planetary backyard:

2020 SV5, measuring 20m in diameter (a little over the size of a typical bowling alley), will shoot past at a distance of 1.2 million km; 2020 SQ, measuring 12m (thats eight Danny DeVitos) will swerve us at a distance of 2.1 million km; and, last but not least, 2020 SO2, measuring 37m (half the wingspan of a 747) will miss us by 6.9 million km.

Meanwhile, NASA boffins are busy preparing for the agencys first-ever asteroid-sampling mission, following in the footsteps of Japanese space agency JAXA's success on board the asteroid Ryugu.

On October 20, NASAs OSIRIS-REx probe will touch down on the 1,640ft-wide (500 meter) space rock Bennu, having hovered in orbit for the past two years.

The end zone is a small crater dubbed Nightingale, with the probe aiming to hit a 26ft-wide (8 meter) boulder-free target zone from which to take samples.

This spot is just the width of a few parking places and is surrounded by large, boulder-like structures the size of small buildings, said Mike Moreau, OSIRIS-REx deputy project manager at NASA's Goddard Space Flight Center.

Itll be a tricky maneuver, as theres an 18-minute delay in signals reaching the rock from Earth. The OSIRIS-REx probe will touch down for just a few seconds with its 11ft-long (3.4 meter) robotic arm, blasting the asteroids surface with nitrogen gas and collecting the debris with a sampling device the team have likened to a car's air filter.

They are aiming to collect roughly 2oz (60g) of space dust from the rock. All going well, OSIRIS-REx will depart Bennu in March 2021 and is expected to land in the Utah desert some time on September 24, 2023.

Think your friends would be interested? Share this story!

Link:

Statue of Liberty-sized space rock among FIVE headed towards Earth warns NASA - RT

What’s the Best Cryptocurrency to Buy in 2020? 7 Contenders – Yahoo News

These are seven of the best cryptos on the market.

It has been over a decade since the mysterious Satoshi Nakamoto created Bitcoin, the first and by far most popular form of cryptocurrency in the world. Despite its fame, Bitcoin isn't the final word on cryptocurrency -- imitators, innovators and spinoffs have emerged in huge numbers, and there are more than 7,000 cryptocurrencies on the market today. With such a broad range of cryptocurrencies to choose from, how do investors know which is the best cryptocurrency to invest in? From the most popular cryptocurrencies making headlines around the globe to lesser-known digital currencies you may never have heard of, here are seven of the best cryptocurrencies to buy in 2020.

Bitcoin (BTC)

The closest thing you'll get to a blue-chip cryptocurrency, Bitcoin has dominated the market since the first bitcoins were mined in January 2009 -- but that doesn't mean it has always been smooth sailing. Bitcoin prices hit a high of nearly $20,000 in December 2017 before collapsing in 2018, bottoming out at $3,234 by the end of that year. Since then, however, Bitcoin has enjoyed something of a comeback as prices have risen back to more than $10,000, and with a market cap around $200 billion, bitcoins account for more than 57% of the cryptocurrency market. Bitcoin has its fair share of volatility, but being the biggest name in crypto gives it a worldwide acceptance that lesser-known rivals don't have, arguably making it the best cryptocurrency to buy for investors new to the asset class.

Bitcoin Cash (BCH)

Cryptocurrencies like Bitcoin are predicated on blockchain technology, which stores information about crypto transactions within "blocks" of data that can contain 1 megabyte of data. As the currency grew more popular, these data blocks filled up, slowing down bitcoin transactions and increasing transaction fees. Some Bitcoin developers proposed a solution that would effectively reduce the amount of data needed in each block, but others believed this would compromise the integrity of the cryptocurrency -- so they created their own version of Bitcoin in August 2017 and called it Bitcoin Cash. Bitcoin Cash has blocks that can store 8MB of data, allowing for faster and more frequent transactions with lower fees. Bitcoin Cash may be newer and less popular than its predecessor, but its scalability means it has incredible potential for growth and puts it in the running for best cryptocurrency.

Story continues

Litecoin (LTC)

Cryptocurrencies tend to seem obscure and complex to those who don't understand the underlying technology, but Litecoin was created to help fix that. In fact, founder Charlie Lee wanted to create the "lite" version of Bitcoin and develop a cryptocurrency that could play the role of "silver to Bitcoin's gold." Lee did just that with Litecoin in 2011, creating a cryptocurrency that adopted many of the best features of Bitcoin with some twists. For instance, while bitcoin transactions take about 10 minutes to confirm, litecoin transactions are far faster, taking under three minutes. In addition, while it takes specialized hardware and impressive raw computing power for users to mine bitcoin, Litecoin has much lower system requirements -- in fact, ordinary PCs are capable of mining for it. Faster and easier is a powerful combination for users and investors alike.

Ethereum (ETH)

One of the main philosophies behind cryptocurrencies is the decentralization of currency. Ethereum takes that a step further -- rather than decentralizing money, Ethereum's goal is to decentralize the internet by replacing servers with a worldwide system of nodes, creating "one computer for the entire world." Ethereum is a software platform based off blockchain technology in which users can exchange a cryptocurrency called ether. Ether has become one of the most popular cryptocurrencies in the world, with a market cap around $40 billion that puts it second only to Bitcoin in market share. But the real draw is the platform itself, which has become wildly popular as a host for other cryptocurrencies -- in other words, not only do investors profit from one of the best and most popular cryptocurrencies on the market, but also from the wider uses of Ethereum itself.

Binance Coin (BNB)

Like Ethereum, Binance Coin is much more than a cryptocurrency -- as a matter of fact, Binance Coin was originally hosted on Ethereum until the Binance decentralized exchange, or DEX, went online in 2017. The Binance DEX is a platform much like Ethereum, albeit with a different mission. The Binance DEX is a decentralized platform where users can not only buy and sell binance coins, but can also use BNB to convert other cryptocurrencies from one to another. This has made the Binance DEX the biggest cryptocurrency exchange on the planet by volume and has helped fuel the popularity of the digital asset. Most importantly, the Binance DEX offers a discount to users who pay transaction fees on the exchange with BNB -- a smart strategy that keeps users on the platform and helps sustain Binance Coin's growth.

Tron (TRX)

This has been a year of extreme upheaval for the entertainment industry, leaving it ripe for disruption. This is exactly the sort of opportunity the founders of Tron must have been hoping for when they built a decentralized, blockchain-based platform for sharing content. Whereas many of the biggest entertainment companies in the world profit from gathering and selling data about their users, using Tron leaves no such footprints behind. While it protects users, Tron also allows creators to monetize their content directly via Tronix, Tron's form of cryptocurrency. The platform has gained fame and notoriety in equal measure over the last few years due to the antics of Tron Foundation founder Justin Sun, but no matter how you feel about him, it's undeniable that Tron is an ambitious idea -- and while it isn't going to overthrow Netflix (ticker: NFLX) tomorrow, it is an excellent speculative investment.

Chainlink (LINK)

The Ethereum platform is predicated on smart contracts, or agreements between two parties on a blockchain network with the transaction recorded in blocks of data. The problem is that these transactions can only occur on a platform like Ethereum, and they need some way to draw real-world data into the platform in order to execute smart contracts when certain conditions are met. The solution is data providers called oracles, and while several crypto platforms have created ways for oracles to retrieve data for their network, Chainlink has come up with a reputation system that guarantees the data is accurate, ensuring the validity of smart contracts -- and once an oracle's data is verified, they are paid with Link, Chainlink's cryptocurrency of choice. This system builds confidence in the platform, and the growing popularity of decentralized finance, or DeFi, helps make Link a contender for best cryptocurrency.

Seven contenders for the best crypto to buy for 2020:

-- Bitcoin (BTC)

-- Bitcoin Cash (BCH)

-- Litecoin (LTC)

-- Ethereum (ETH)

-- Binance Coin (BNB)

-- Tron (TRX)

-- Chainlink (LINK)

Mark Reeth is a contributing writer for U.S. News & World Report, where he writes about anything and everything to do with investing. Prior to U.S. News, Mark covered consumer goods, technology, and telecom stocks for The Motley Fool. When he's not writing about investment strategies Mark is busy running his own small business, which has given him a better appreciation of the personal finance trials and tribulations of entrepreneurs everywhere.

Mark is a graduate of the College of the Holy Cross, where he studied History and Education. You can connect with Mark via LinkedIn, or follow him on Twitter.

Read the original:

What's the Best Cryptocurrency to Buy in 2020? 7 Contenders - Yahoo News

One of Hal Finney’s lost contributions to Bitcoin Core to be ‘resurrected’ – Cointelegraph

In a February 8, 2011 post on Bitcointalk, Finney said that reading a book titled Guide to Elliptic Curve Cryptography by Hankerson, Menezes, and Vanstone, gave him an idea of how to speed up signature verification by 25%. In the following post from the same day, Finney announced that he had already written test code and uploaded it to the Github repository. However, there was a problem with Finneys proposal his method had already been patented by someone else.

Method for Accelerating Cryptographic Operation on Elliptic Curves (also known as GLV or Four-Dimensional GallantLambertVanstone Scalar Multiplication) received a patent on September 19, 2006 likely at a time when Satoshi Nakamoto was already busy at work on Bitcoin (BTC). In order to understand the invention, we have to dive a bit deeper into elliptical curve cryptography. The patent reads:

The improvement comes from representing the scalar k as a combination of components k, and an integer A. Mathematical operations performed on k represented in this form appear to be less computationally expensive, hence the gains in speed.

Finneys 2013 proposal was implemented with the release of the libsecp256k1 library, but was never enabled due to existing legal concerns. That's how things stood until September 25, when the patent expired. According to the Blockstream co-founder Adam Back, the code is now expected to be activated in the next Bitcoin Core update.

February 2011 seems to be the time when Finney was most focused on optimizing Bitcoin's signature verification. In a post from February 7, 2011, Finney said he was looking at batch signature verification, which he believed might speed up the process by a factor of four. The idea behind it was that instead of verifying signatures one by one, to verify them block-wise: hundreds or even thousands at a time. However, according to Blockstreams co-founder Pieter Wuille (who was one of the authors of the libsecp256k1 library), when GLV is combined with batch verification, the gains disappear once you reach approximately 1,000 signatures:

Indeed, it has been implemented for Schnorr signatures where it affords two-fold gains in speed. Back indicated that he expects a forthcoming release of Schnorr signatures which include batch verification:

It is unlikely that Finneys cryogenic housing allows for any movement, but if it did, we might get a sneak of a smile on his face.

Originally posted here:

One of Hal Finney's lost contributions to Bitcoin Core to be 'resurrected' - Cointelegraph

Latest Bitcoin price and analysis (BTC to USD) – Coin Rivet

Bitcoin is edging towards a long-awaited breakout above the $10,930 level of resistance after surging by 1.95% from yesterdays low of $10,677.

The worlds largest cryptocurrency has been trading beneath $10,930 ever since the break down in price on September 21.

The most recent price hike comes after a week of consolidation that saw Bitcoin struggle to pick up meaningful trade volume or momentum.

However, an overnight surge in trade volume across all major exchanges resulted in a swift switch in sentiment, which in turn prompted a move to the upside in terms of price action.

When examining the daily relative strength index (RSI), it was clear that between July 28 and September 1 there was worrying signs of bearish divergence as price traded in a sideways formation.

BTCUSD chart by TradingView

This time around, The RSI has been creeping up a faster rate than the price, indicating small signs of hidden bullish divergence which could well lead to a break up in price.

Three years ago Bitcoin was on the brink of rallying to its all-time high of $20,000 as excitement around ICOs and altcoins reached a notable crescendo.

DeFi has effectively displaced the ICO boom of three years ago, with investors now flocking to decentralised exchanges like Uniswap to pick up yield farming tokens like YFI and CORE.

Once investors take profits on these type of tokens, capital will often flow back into Bitcoin before it can enjoy a rally to the upside itself.

For more news, guides and cryptocurrency analysis, clickhere.

Current live BTC pricing information and interactive charts are available on our site 24 hours a day. The ticker bar at the bottom of every page on our site has the latest Bitcoin price. Pricing is also available in a range of different currency equivalents:

US Dollar BTCtoUSD

British Pound Sterling BTCtoGBP

Japanese Yen BTCtoJPY

Euro BTCtoEUR

Australian Dollar BTCtoAUD

Russian Rouble BTCtoRUB

In August 2008, the domain name bitcoin.orgwas registered. On 31st October 2008, a paper was published called Bitcoin: A Peer-to-Peer Electronic Cash System. This was authored by Satoshi Nakamoto, the inventor of Bitcoin. To date, no one knows who this person, or people, are.

The paper outlined a method of using a P2P network for electronic transactions without relying on trust. On January 3 2009, the Bitcoin network came into existence. Nakamoto mined block number 0 (or the genesis block), which had a reward of 50 Bitcoins.

If you want to find out more information about Bitcoin orcryptocurrenciesin general, then use the search box at the top of this page.Heres an article to get you started.

As with any investment, it pays to do some homework before you part with your money. The prices of cryptocurrencies are volatile and go up and down quickly. This page is not recommending a particular currency or whether you should invest or not.

Disclaimer: The views and opinions expressed by the author should not be considered as financial advice.

Continued here:

Latest Bitcoin price and analysis (BTC to USD) - Coin Rivet

CoinGeek Live Day 1 looks at Bitcoin’s ‘fusion of data and money’ – CalvinAyre.com

The first day of CoinGeek Live saw several Bitcoin experts explaining how the future of money and the internet will look with Bitcoin SV. This 3-day conference kicked off with a focus on payments, financial services, regulation, and the newest developments on the BSV blockchain.

The day kicked off with a message from Bitcoin AssociationFounding President Jimmy Nguyen. He focused on the history and vision of Bitcoin, and its destiny as the one world chain. Thanks to BSV returning to the original protocol set out by Dr. Craig S. Wright, under the pseudonym Satoshi Nakamoto, Bitcoin is now providing immense business power by acting as a ledger for not just payments, but data as well. Its a fusion of data and money, Nguyen said.

Unlike the other blockchains that have popped up since 2008, Bitcoin will act as the foundational rule set for an entire network, Nguyen said, and is re-inventing the internet.

To do that, Bitcoin has to grow, and BSV has been allowed to scale massively. BSV currently processes over 2,800 transactions per second, and is looking to hit 50,000 in the near future. Thats because any blockchain hoping to serve enterprise needs has got to scale, Nguyen said, and it has to scale big.

Following that opening address, Steve Shadders, CTO of nChain and Technical Director of the Bitcoin SV Node project, spoke about the last missing pieces to truly realize the peer to peer vision that was layed out by Satoshi Nakamoto in his 2008 white paper. He then broke down several of the new technologies BSV has introduced that makes it easier to send transactions, with the newest method, Simplified Payment Verification (SPV) channels demonstrated live on stage.

Later on in the day, Dr. Craig S. Wright spoke about another important new concept for the BSV blockchain, PUFS (Physical Unclonable Functions.) Internet of Things devices will be able to use PUFS to work better together, and solve identity problems on the network.

From there was an exciting new way of monetizing the virtual world. Robert Rice, Founder & CEO of Transmira Inc. introduced OmniScap, a blend of Virtual Reality and Augmented Reality that can help monetize a virtual world with Bitcoin SV. Imagine having a casino built in VR, with the ability to monetize every game and area the user visits. That can happen.

Thats not the only reason the gambling industry might want to check out Day 1 of CoinGeek Live. There were several panels featuring payment companies like Anypay, Zumo, Gap 600, CENTI Ltd. There was insight into the finance and banking sector from the Swiss National Bank, Drawbridge Lending, White Company, and talk of regulation with a panel of lawyers, government lobbyists and a former regulator.

You can watch all of it below. And if you havent signed up to watch CoinGeek Live yet, what are you waiting for? Day 2 is happening today, it offers great networking opportunities, and its free to watch by signing up at CoinGeekConference.com.

Follow this link:

CoinGeek Live Day 1 looks at Bitcoin's 'fusion of data and money' - CalvinAyre.com

Forex Forecast and Cryptocurrencies Forecast – Action Forex

First, a review of last weeks events:

EUR/USD. The question that we tried to resolve last week was whether this pair will continue its fall or return again to channel 1.1700-1.2010. Experts couldnt give any clear answer then. Their votes were divided as follows: 30% favored the fall of the pair, 30% favored its rise and 40% took a neutral position. As a result, the pair surely did not continue to fall, but it is also difficult to call its movement returning to the channel: having reached the local high at 1.1700 on Thursday, October 01, the pair turned around and completed the five-day period at 1.1715.

Investors were not particularly impressed by the fact that the Democrats in the US House of Representatives passed legislation on a new package of economic stimulus worth $2.2 trillion, especially since it was previously about $3 trillion-plus. The US labour market data didnt have much impact on anything either. ADPs September Private Sector Employment Report showed an increase to 749K, up from 481K a month ago and a 650K forecast. The number of new jobs created outside the agricultural sector (NFP), on the contrary, turned out to be less than both the August and forecast values: 661K in September, 1489K in August against the forecast for September 850K.

Investors were much more impressed by the news of the infection of US President Trump and the first lady with coronavirus. When this information appeared, the US dollar and the Japanese yen went up, but then the question arose, how serious this disease is and how it could affect the economic situation in the United States and in the world. And before at least some clarity appeared, the market paused, and the EUR/USD pair moved to a sideways movement in a narrow range of $ 1.1685-1.1770, within which, as already mentioned, it came to the end of the weekly trading session;

GBP/USD. Against the background of Brexit uncertainty, the pair returned to the range where it was already trading on September 15-21 1.2805-1.3000, thus confirming the forecast given last week by 35% of analysts, graphical analysis and 15% of oscillators that signaled the pair was oversold. After a jerk up by 230 points, the strength of the bulls dried up, they could not break through the resistance of 1.3000, and the pair completed the five-day period in the area of 1.2935;

USD/JPY. The last week cannot be called remarkable for the Japanese currency. Until Friday, the pair moved in a very narrow channel 105.30-105.75, and it was only on the news of the positive test for coronavirus by Donald and Melania Trump that the pair jumped down, reaching 104.95. This movement showed that, in such a critical situation, investors are likely to intuitively prefer yen, considering it a safer protective asset than the dollar. Although, a 70-point drop in the dollar could hardly be considered a major loss. Moreover, later the situation stabilized, the pair went up, and its final chord sounded at the level of 105.35;

cryptocurrencies. We started our previous analytical review of the digital market with the phrase: Another attempt by bitcoin to gain a foothold above the $11,000 mark ended in another failure. the same can be said about the outgoing week. Having bumped their heads against the ceiling of $10,940-10,970, the bulls gave up and the BTC/USD pair rolled back to the $10,400-10,500 zone, which fully confirmed the forecast, which was voted for by the majority of experts (65%). As for the Crypto Fear & Greed Index, it has dropped slightly over the past seven days, from 46 to 41, and is still in the neutral zone.

According to analyst portal Messari, this is the first time that daily bitcoin candles close above $10,000 for 63 consecutive days. The previous longest series was 62 days and was registered from December 1, 2017 to January 31, 2018, when bitcoin reached an all-time high near $20,000, having risen in price by 100% in two weeks. At the same time, the cryptocurrency was held above $11,000 for 50 days, and above $12,000 for 41 days.

According to the experts of the WhaleMap analytical service, bitcoin is now prevented from falling below $10,000 by large investors who begin to replenish their reserves as soon as the value of BTC approaches this level. It is for this reason that at the week high, the total capitalization of the crypto market, despite the drop in quotations, grew to $350 billion. However, on October 01-02, another sale of coins dropped it to $330 billion once again.

The dynamics of the cryptocurrency market is increasingly dependent on the mood in the traditional markets and is subject to changes in the risk appetite of investors. The latter in turn depend on the situation with the coronavirus and the reaction of regulators to it.

According to experts of Galaxy Digital Capital Management, bitcoin is beginning to be perceived by institutional players as an inflation hedge, that is, as a kind of insurance in case the US dollar loses the status of the world reserve currency. Comparing the capitalization of gold (more than 12 trillion dollars) and bitcoins (about 200 billion dollars), analysts of this company conclude that the situation will level out towards the main cryptocurrency, into which there will be an outflow of investments from the precious metal, which may raise its value 60 times in the future.

If you look at the results of the first 9 months of 2020, it becomes obvious that the COVID-19 pandemic has already benefited bitcoin. Even despite the panic of late February early March, the coin has risen in price by about 40% (gold by 25%). If we take March 13 as the starting point, then during this period the main cryptocurrency has grown 2.75 times (gold 1.3 times).

This situation also contributed to the growth of cryptocurrency fans. A study by the Cambridge Center for Alternative Finance says about 100 million people already own bitcoin and other coins in the world. In 2018, there were about 35 million of them, that is, three times less. The lions share of BTC and other coin holders live in North America and Europe, followed by Latin America and the Asia-Pacific region. As of the end of the third quarter of 2020, up to 191 million addresses were registered on cryptocurrency exchanges.

As for the forecast for the coming week, summarizing the views of a number of experts, as well as forecasts made on the basis of a variety of methods of technical and graphical analysis, we can say the following:

EUR/USD. 65% of analysts supported by graphical analysis on H4 expect that the dollar will be able to strengthen its position somewhat in the coming days, and the pair will once again test support of 1.1600. This is opposed, respectively, by 35% of experts and graphical analysis on D1, according to which the EUR/USD pair, having returned to the 1.1700-1.2010 range, will continue to move towards its central part and will consolidate in the 1.1800-1.1900 range in the second half of the week.

Oscillators and trend indicators do not give any signals that are more or less suitable for forecasting. Particularly important macro statistics are not expected these days either. Interest may be caused by the speeches of the head of the US Federal Reserve Jerome Powell on Tuesday October 6 and his European counterpart Christine Lagarde on Wednesday October 7. The minutes of the US Fed Open Market Committee meeting will be published on the same day.

However, the main intrigue of the week will undoubtedly remain the health of the Trump presidential couple. If the old enough president of the United States quickly returns to full-time work, it will become a good trump card in his election race. Thus, he will be able to show that he assessed the degree of danger of coronavirus correctly and took adequate measures to combat the pandemic in the United States. If the symptoms of the disease turn out to be severe, this will not only force Trump to curtail the election campaign, but, showing the seriousness of the threat, will turn many doubting voters against him;

GBP/USD. Due to the growth of the pair last week, the overwhelming majority of indicators (85%) are colored green. But will this trend continue in the future?

It is clearly not worth looking for the answer to this question in the readings of the indicators. As of Friday evening October 02, when this forecast is being written, Brexit news remains more than contradictory. British Prime Minister Boris Johnson is due to meet European Commission President Ursula von der Leyen on Saturday 03 October. How this meeting will end is anyones guess so far. And then another factor of uncertainty arrived in time the infection of Donald and Melania Trump with the COVID-19 virus. That is why the analysts opinions are distributed as follows: 40% support the growth of the pair, 40% are for its fall and 20% have taken a neutral position. The nearest target of the bears is 1.2675, followed by support in the 1.2500 zone. The bulls task is to break through the resistance at 1.3000 and return the pair to the echelon 1.3000-1.3200;

USD/JPY. Graphic analysis both on H4 and D1 shows the pairs decline to the lowest of the past week in the 105.00 zone, and then another 100 points lower, where it already visited on July 31 and September 21. Resistance in this case will be the level of 105.80.

After completing this trip to the south, according to the graphical analysis on D1, the pair should return to the zone 105.00-106.00, and go further north by the end of October, to 107.00.

The bearish sentiment is also supported by 85% of the experts, as well as about 70% of the indicators. Analysts forecasts are largely influenced by the situation with the coronavirus pandemic in the United States, which has now directly affected the Trump couple. And thats just a month before this countrys presidential election. However, this situation can change very quickly, and then the scenario will be realized, for which only 15% of experts have now voted, according to which the pair will go up and quickly reach the zone 106.55-107.00;

cryptocurrencies. The number of bitcoins mined exceeded 18.5 million units. Just under 12% of the total issue or less than 2.5 million coins remain available for production, most of which could be mined in the next four years and the last coin in 2140.

Recall that according to the algorithm established by the creator of bitcoin Satoshi Nakamoto, the total amount of coins is 21 million, and halving occurs every four years the reward for miners is halved. The main task of halving is to control the issue of cryptocurrency and its inflation.

Bitcoin miners expect a repeat of the rally of the main coin of three years ago. Many market representatives are confident that there are all conditions for the cryptocurrency market to move into a stage of active growth now. It is about snatching the main coin to $20,000.

The head of the Crypto Quant trading platform, Ki Yong Joo, noted that signals for a return of bullish sentiment to the market began to appear in mid summer, but strong external factors opposed the rise in the value of the coin then. There is no denying that mining pools are having a major impact on the cryptocurrency market. It is worth remembering the consequences of the halving this May, when the hashrate of the main coin dropped for a while. Growth in such conditions became impossible, so investors and holders of the asset moved to wait-and-see tactics. The situation is completely different now. Miner Position Index (MPI) continues to strengthen. They try to mine as many blocks as possible for maximum rewards. The hashrate of bitcoin is also stable at high rates, Joo said.

Bloomberg Intelligence chief commodities strategist Mike McGlone expects growth as well. He believes that the first cryptocurrency should be valued at $15,000. He came to such conclusions based on the dynamics of growth in the number of active addresses since 2017. At the same time, he estimates the likelihood of alternative scenarios as low.

As for the current forecast, almost everything is the same here: the lower bar of the trading range for the BTC/USD pair is $9,500, the main support is $10,000, the main resistance is $11,000. At the same time, the probability of the next attack of bulls to this height, according to experts, is close to 70%, and the probability of consolidation above this level is twice lower.

Read more:

Forex Forecast and Cryptocurrencies Forecast - Action Forex

What is Lightning Network? And How to Use It in 2020 – Decrypt

In brief

Bitcoin has been hampered by its own popularity. Thanks to the way the blockchainis designed, the speed of transactions is slow and the cost of transactions has gone up.

Researchers, developers, and the Bitcoin community have been trying to come up with a way of allowing Bitcoinand other cryptocurrenciesto accommodate more transactions. Their best efforts to date have focused around something called the Lightning Network. Can it fix the cryptocurrency's scaling problems? We find out below.

There are two limitations we need to explain when it comes to blockchain before we can explore how people are trying to fix it.

The first is speed.

In a blockchain, blocks are essentially groups of transactions collected together. As part of a blockchains design, there are only so many transactions that can be included in a block.

If your transaction doesnt make it into the current block, it joins a queue. That queue can take anywhere from a few minutes to potentially a day or more to process, depending on how many other transactions are queued in the mempool.

That limits the blockchains use as a medium to process quick transactions, like buying a cup of coffee. No one wants to wait around for the network to verify youve got the cash.

The second limitation is cost.

Bitcoins network, and others, arebuilt upon a consensus protocol called proof of work.

This is where miners expend energy trying to solve a difficult puzzle. To help offset the cost of equipment and energy used in that calculation, miners charge transaction fees.

When the system is small, and the number of transactions that need verifying are few and far between, the network works well and transaction costs are low. As the network grows, however, so does the cost of transaction fees, since there is limited space in each newly mined block. As a result, only the highest fee transactions are processed highly during times of high load.

Bitcoin's scalability challenge became apparent towards the end of 2017 when millions of people jumped on the Bitcoin bandwagon and it struggled to cope with the number of transactions. At its peak in December 2017, the average cost to process one transaction on the Bitcoin blockchainwhether it was for $1 or $1,000was $37. That makes Bitcoin un-economical as a form of currency, since the transaction fee would be higher than the actual payment for many small transactions. Thats where the Lightning Network comes in.

We've got a whole article explaining more about Bitcoin's limitations.

The Lightning Network is a second-layer solution built on top of the Bitcoin network, meaning that it is built separately to the Bitcoin network but interacts with it. Its made up of a system of channels that allow people or companies to move money between one another without needing to use the blockchain to verify the transaction.

In theory, it could allow thousands or even hundreds of thousands of transactions to take place instantly, making it great for small transactions.

It bears similarities to the current settlement system used by companies like Visa and Mastercard. When you pay for something its not instantly settled.

Instead, theres a quick verification of funds from the buyer and the request from the sellergiving the green light for a transaction to take place.

The settlement of the funds happens laterin some cases days or weeks later.

The Lightning Network is run by a network of nodes that process payments, and transactions are commonly made using QR codesinstead of complex public keys.

The bottom line is that it allows for faster payments, with lower fees.

The Lightning Network has its origins in musings by Satoshi Nakamoto, the pseudonymous creator of Bitcoin, but was formalized by researchers Joseph Poon and Thaddeus Dryja who published awhitepaper for the Lightning Network on January 14, 2016.

In it, they argued that a network of micropayment channels could fix the scalability issues of the Bitcoin network, rather than changing the Bitcoin network itself to allow more transactions.

Lightning Labs, a blockchain engineering lab, helped to launch a beta version of the Lightning Network in March, 2018alongside a host of individuals and other companies including ACINQ and Blockstream. It was funded via a $2.5 million seed investment round, which included notable investor Twitter CEO Jack Dorsey (who has recently been getting more involved). The Lightning Network was the first attempt at a second-layer solution, but others followed.

Jack Dorsey, the CEO of Twitter is a big fan of the Lightning Network and has personally invested in the project!

The Lightning Network speeds up transactions, while reducing costs, by skirting the main Bitcoin blockchain. It is an unstructured network set up around it.

Channels are the ad hoc, peer-to-peer connections through which payments are made. Any number of payments can be sent in a channel.

The network is maintained by nodes that route payments. Nodes are run by everyday peopleor corporationsrunning a program on their desktops, laptops, or Raspberry Pis. This keeps the Lightning Network decentralized.

To start using the Lightning Network, any amount of Bitcoin needs to be locked up in a payments channel. Then, it can be spent across the Lightning Network, until the channel is closed.

When someone wants to receive a transaction, they create whats known as an invoice. These are a long alphanumeric string of digitswhich is often represented using QR codes. The person who wants to make the payment simply needs to scan this invoice with their Lightning Wallet and confirm (by providing a digital signature) that they want to make the payment.

When a payment is made, the confirmation is sent across the network to the person who originally made the request. This is known as a peer-to-peer network and means the processing of payments is not reliant on any one party. This typically happens in just a few secondshence the name Lightning.

Since payments are not made on the Bitcoin blockchain, they are not subject to long wait times and high fees. This means that much smaller payments, or micropayments, can be made for as little as one satoshi (one hundred millionth of a Bitcoin). This makes it more suitable for everyday transactionswhile larger transactions can be made on the Bitcoin network.

Once someone has finished using the Lightning Network, they can close their channel and exit the network. This means they can use their Bitcoin again on the standard Bitcoin network.

For a more complex, technical introduction to the Lightning Network, check out Lightning Labs CEO Elizabeth Starks guide on Coincenter.

Lets say you want to transact with your local coffee shop. First, youd need to send some Bitcoin to a wallet that requires more than one signature or key to release the funds.

These are commonly referred to as multisig wallets. These multisig wallets require more than one signature in order to release funds. In the case of the Lightning Network, it allows people to enter into an agreement that ensures they receive the agreed payment. In effect, creating a balance sheet.

Every time you buy a cup of coffee you create a new balance sheet and sign it with your public key to reflect whats left in your wallet, and whats in the coffee shops wallet.

If you dont want to buy coffee anymore from that coffee shop, you can close the channel, and the resulting balance sheet is committed to the blockchain as a permanent record.

Payment disputes can also be settled by referring to the last signed balance sheet between the two parties.

What happens if you dont have a direct channel with the next place you want to buy something from? The network will find the shortest route between you and the shop via others in the network.

Although it was originally designed for Bitcoin, the technology is currently being adapted and developed for a range of cryptocurrencies which include Litecoin, Stellar, Ether, and Ripple.

Its already live! The first version was launched on Bitcoin in March 2018 and has started popping up in different places. One of the most recent is Twitter!

You can connect to the Lightning Network either by running a node or by using a Lightning wallet. Here are our top picks:

Bitcoin Lightning Wallet on Android

If you dont want the full-node experience, you can download the Bitcoin Lightning Wallet app on your Android phone, which sorts everything out in the background and lets you connect to the Lightning Network. With this, you can open a Lightning channel and start making transactions to other users. Its also non-custodial, meaning you look after your own keyskeeping your Bitcoin in your hands. (We tried it out by paying for ataxi ride).

Read our review of the Bitcoin Lightning Wallet.

Blue Wallet on iOS and Android

If you want to use the Lightning Network but dont want to look after your own funds, Blue Wallet is a custodial service that runs a node for you. It allows you to send and receive Lightning payments, but doesnt let you withdraw your Bitcoin from the Lightning Network.

It also has a Lapps marketplace. Lapps is a portmanteau for Lightning apps and are apps that use the Lightning Network, the way decentralized applications (or dapps) run on regular blockchains. So far, there are only a few Lapps, such as Bitrefill for paying phone bills, and ZigZag for exchanging cryptocurrencies. As Lightning picks up steam, expect the number of Lapps to grow, too.

Casa Node

To get the full Lightning Network experience, you can try running a full node. Sounds complicated? It isnt, actually. The folks at Casa have put everything you need in one box, so all you have to do is plug the Casa Node into itself, weirdly enough, and youre up and running.

So what does this mean? Well for a start youre now supporting the Bitcoin network and the Lightning Network by checking that transactions are legitimate. It also means you can connect it to your computer and make transactions from your own node. This literally makes you your own bank; you are the only person owning and controlling your funds. Scary, huh?

Read our full review of the Casa HODL node.

Eclair Lightning Node

If youre feeling more ambitious, you could set up a full Lightning Node. This takes a lot more computer know-how to run. It means downloading Eclair onto your computeror a homemade Raspberry Piand running it. You are then routing transactions on the network and can make your own transactions.

Eclair also offers a mobile version for Android users called Eclair Mobile. This is a stripped-down Lightning node, which means you stay in control of your Bitcoin. You can connect it to your own Eclair Lightning Node if youre running one. Theres only one catch: you cant receive payments to it. Eclair explains why in this blog post.TL;DR its safer and easier for them.

Lightning Joule

Once youve set up your own node, what next? Are you stuck with using a desktop app? Lightning Joule is a browser extension that lets you connect your Lightning Node to your browser so that you can easily make payments within Chrome, Firefox, Opera and Brave. Its a convenient hack.

For a start, you can make payments to anyone else who has a Lightning wallet set up. But theres more to the Lightning Network than just that. As it is a digital currency, it is easily integrated into websites without the need for third parties to get involved.

Although the vast majority of crypto companies dont yet accept Lightning transactions, the number of platforms that do is slowly growing. Nonetheless, a wide range of popular Lightning-capable platforms are currently operating, ranging from cryptocurrency exchanges like Bitfinex and MercuriEX, online retailers and merchants like Bitrefill, as well as a wide range of casinos, and other service providers.

If you are looking for somewhere local, then you might be able to find something nearby on Accept Lightning or on the Lightning Network Stores.

Here are some examples of things you can do with the Lightning Network:

Get some satoshis with a Lightning Faucet

You can get some more Bitcoin. Faucets have long been a way to distribute small amounts of Bitcoin and other cryptocurrencies, and its no different with the Lightning Network. This Lightning Faucet lets you test sending and receiving from a Lightning wallet; you can withdraw a maximum of 100 satoshis every 4 hours, which is just over $0.01. Got to start somewhere though.

Buy a Dominos pizza

Feeling hungry? Before you reach for your debit card, why dont you try ordering your pizza with the Lightning Network. Thats right, Lightning Pizza will order a Dominos pizza on your behalf once youve paid them in Bitcoinbut only if youre in the US, though. Of course, its not the only way to buy pizza with Bitcoin.

Tip people in Satoshis on Twitter

Do you wish social media was more rewarding? Well now it is. You can tip other peopleand they can tip youin Bitcoin using the Lightning Network. Simply integrate Tippin.me and it puts a little lightning symbol on every tweet.

You will need your own wallet to send tips (see above). All the cool kids are doing it, like Jack Dorsey, cofounder of Twitter.

Its hard to grasp something that involves thousands of little parts, making millions of interactions with each other. Its a bit like trying to picture everything going on in your brain. So, to make this a bit easier, we have used a number of visual diagrams. This is what the Lightning Network looks like from above.

A great resource for Lightning Network data is 1ML, a search and analysis engine. It provides data on which stores accept Lightning payments and information about current nodes. But it also features a spectacular visualization of the Lightning Network, showing all the nodes and how they are connected to one another. Check it out below.

For the more topologically minded of you, here is a map showing the locations of many of the Lightning Network nodes and how they are connected. You can see that there are three main areas where they are concentrated but that some exist in the far-flung reaches of the world. Expect this map to become much more cluttered as time goes on.

If that wasnt trippy enough, heres a 3D view of the Lightning Network that you can explore. And if you want to dive even deeper inside the network, you can don VR glasses to get the full experience.

This visualization makes the Lightning Network look like some kind of futuristic planet. This is the view from one persons node. The larger the areas, the more Bitcoin in the Lightning channels. Interestingly, the large blue area on the right is called DeutscheTestnetBank, whoever that might be.

The Network faced its first major hijack on March 20, 2018 when a distributed denial of service attack took down around 200 Lightning nodes, about 20% of the network at the timemeaning that the network struggled to process any transactions. After preventative measures were put in place, it grew to reach a total of 7,000 nodes.

Since then, the Lightning Network has continued to grow. As of our most recent update (September 2020), there are just shy of 13,900 Lightning nodes and over 37,000 channels in operation. The total network capacity of the Lightning Network now sits at 1,098 BTC (or around $11.4 million at current values).

Each Lightning node is responsible for interacting with other nodes to help transact money, while the channels are essentially the highways that enable money to be moved between nodes on the network. The more nodes and channels there are, the easier it is for larger transactions to complete successfully.

Overall, the total network capacity has grown by 40.7% in the last year, while the average capacity of each channel has grown 22% to reach $331 over the period. Due to a lack of pathways for some transactions, the Lightning Network still remains of limited use for large transactions in most cases.

A recent episode of The Pomp Podcast does an excellent job of covering the current progress and limitations of the Lightning Network, and features key insights from Jack Mallers, the founder of one of the most commonly used Lightning walletsZap.

The popularity of cryptocurrencies and transacting on them has, within just a few short years, put increasing stress on the blockchains theyre built on.

While there have been smaller changesand some cases forksto help the networks better cope with demand, the Lightning Network, if successful could help open the door to widespread adoption of cryptocurrencies and their applications.

In August 2020, the Lightning Network was updated to include support for the Wumbo function. In the early days of Lightning, the developers limited how much Bitcoin could be kept inside a Lightning payment channel to 0.1677 BTC; Wumbo channels enable nodes to service larger transactions and higher volumes. Crypto exchange Bitfinex is among those who've announced support for Wumbo channels.

The Lightning Network is spreading beyond Bitcoin, too. Blockstream has created its own implementation of the Lightning Network called c-Lightning which is built in the C programming language, familiar to most developers. Litecoin has its own version, toothe Litecoin Lightning Networkwhich is small compared to the Bitcoin version, but is slowly growing.

For more resources on the Lightning Network, check out Jameson Lopps resources page here.

Read this article:

What is Lightning Network? And How to Use It in 2020 - Decrypt

Trump is receiving lots of medical care, and some doctors wonder if it’s too much. – USA TODAY

President Trump's doctor said Trump is not currently on oxygen, but would not say whether he ever received oxygen since his COVID-19 diagnosis. USA TODAY

One potential downside to being president of the United States:too much care.

Presidents have always received VIP medicine, but excessive care isnt necessarily good quality care, said Dr. J. Randall Curtis, a professor of pulmonary and critical care at the University of Washington School of Medicine in Seattle.

The concern is that having too much focus and too many people involved could result in overtreatment as President Donald Trump is treated for COVID-19 at Walter Reed Military Medical Center.

At a news conference Saturday, officials saidTrump's medical team included threepulmonary critical care specialists, twoinfectious disease doctors, an anesthesiologist, an Army nurse, fourNavy nurses,a clinical pharmacistand the director of the medical center's executive medicine program. That's in addition to the president's physician, Navy Cmdr. Sean Conley.

Live updates on Trump and COVID-19: Sunday's latest news

Trump's health: President reports feeling better but next few days are 'the real test'

Autoplay

Show Thumbnails

Show Captions

Conley said Saturday that he was using a "multi-prong" approach to treat Trump.

"He is receiving all of the standard of care and beyond for routine, international COVID protocols," Conley said. "He's the president. I didn't want to hold anything back. If there was any possibility that it would add value to his care and expedite his return, I wanted to take it."

Curtis acknowledged that as president, Trump and his medical team would want to have lots of input and options. Even so, other physicians noted overtreatment can be an easy trap to fall into with high-profile patients.

It is common for people who hold positions of stature to get more aggressive care because theres pressure to give someone everything imaginable. I would hope his physicians are being very deliberate in the treatment, said Dr. Russell Buhr, a professor of pulmonary and critical care medicine at the University of California-Los Angeles.

That could explain why the president is receiving relatively aggressive treatmentfor someone whose physician has described himas doing very well.

I dont think we can speculate on the reasons behind the care, Buhr said.

What do you want to know about Trump and COVID-19? We are answering reader questions. Submit your own using this form.

Remdesivir as a treatment: Trump was given it to fight his COVID-19 infection. What to know about it

Once Trump was hospitalized, his doctors began him on a course of remdesivir, a prominent experimental drugin the fight against the coronavirus that some clinical trials have shown canshorten the duration of the illness.

They later added the steroid dexamethasone, which has been shown to be life-saving in the sickest COVID-19 patients, but potential dangerous earlier in the course of the disease.

President Donald Trump and first lady Melania Trump tested positive for COVID-19. Here's a look at where he traveled the week before his diagnosis. USA TODAY

A number of doctors and researchers reacted with dismay to the long list of drugs and vitamins Trump had been given during andbefore his hospitalization. Many of them have no strong evidence to support their use and none have been studied in combination.

"It's bad medicine and it's a bad message," said Dr. Vinay Prasad, a hematologist-oncologist at the University of California-San Francisco, who studies health policy, clinical trials and medical decision-making.

Bad medicine because of the lack of proof, he said, and a bad message because it suggests important people don't need to wait for the scientific process to unfold before getting access to unproven medicines.

Some medications will be safe and helpful, others will be unsafe and unhelpful or somewhere in between, and only rigorous clinical trials can reveal the difference, Prasad said.

"The best medicine is not to give drugs that have no proof," he said.

"It is interesting and a bit concerning that they are trying so many therapies that are both experimental and unproven," said Dr. Alden Landry, an emergency medicine physician at Beth Israel Deaconess Medical Center in Boston. "This is not the typical treatment for patients especially at this (early)stage of the virus."

All treatments carry risks, and any one of the therapies Trump is taking might be harmful alone or in combination with other therapies, the doctors said.

What Trump has not been given is hydroxychloroquine, the malaria drug he had touted with little evidence and took briefly himself this spring. Studies since then have shown the drug is ineffective against COVID-19 and can be dangerous.

Trump had asked about the drug, Conley said Saturday, but was not receiving it.

Was Trump ever on oxygen?Health, security experts say America needs 'total honesty' on president's condition

Steroids are commonly given to reduce inflammation during an infection, and dexamethasone has been shown to reduce deaths among the sickest COVID-19 patients.

Earlier in the course of COVID-19, steroids can actually be dangerous, though, because they tamp down the body's immune response, Topol said.

"(My)main concern is the suppression of the immune response he needed," Topol added via email, "nd throwing in unnecessary, and experimental drugs and unknown interactions."

Several doctors also wondered whether adding dexamethasone to the president's prescription list suggests he is more seriously ill than his doctors have admitted.

"If he IS truly sick enough to warrant dexamethasone and his doctors are not just throwing spaghetti at the wall, then the use of dexamethasone means they are minimizing how ill he is in their public pronouncements," said Dr. Nicholas Christakis, a physician and sociologist at Yale University, and author of a forthcoming book on the pandemic, called

.

In one British trial, COVID-19 about 20% of patients who needed oxygen and got dexamethasone died within a month of receiving the drug. "You add in Trump's age and sex and obesity, it is not hard to feel he is facing a risk of death of perhaps 25%," Christakis contined. "That is quite serious, most doctors would say."

When people battle disease, their immune system produces antibodies specific to that illness. With monoclonal antibodies, drug companies try to provide these same protective molecules to boost a patient's immune response.

Conley said Trump received an 8-gram dose of a drug, REGN-COV2, made by the pharmaceutical company Regeneron. It includes a combination of two monoclonal antibodies now being tested against COVID-19. Because it is still considered experimental REGN-COV2 is not yet available to the general public outside of clinical trials.

Dr. James CroweJr., who directs the VanderbiltVaccine Center in Nashville, Tennessee, said the downside of delivering more than one antibody is that it can dilute the power of the most potent one. The plus side is the virus is unlikely to escape when it is hit by two monoclonal antibodies at once, said Crowe, who is developing a different monoclonal antibody with drug giant AstraZeneca.

Regeneron recently released an analysis of its cocktail in 275 patients, showing it to be safe and to reduce a patient's viral load,though there's still no basis yet to conclude whether it is effective.

Dr. Rajesh Gandhi, an infectious disease physician at Massachusetts General Hospital and Harvard Medical School in Boston, said he has given a similar drug made by Eli Lilly and Co. to his patientsand is optimistic about the approach.

"We think antibodies are most likely to work if given early," Gandhi said, which is probably why it was tried on the president so soon after his diagnosis. In many diseases, early treatment is more effective, he said, noting that although the antibodies are promising, they are still experimental."

Dr. Ilan Schwartz, an infectious disease expert at the University of Alberta in Canada, agreed that it was reasonable to give Trump the antibody cocktail. "I think there's enough data to support that it's probably safe," he said. "It's certainly not ready for prime time, but in exceptional circumstances, it would be reasonable (to give to a patient)."

Dr. Eric Topol, director and founder of the Scripps Research Translational Institute in La Jolla, California, said he was surprised at how quickly Trump was able to obtain a dose of the experimental antibody mixturewithin just a day of his diagnosis.

"They're pulling out all the stops," Topol said. "You just don't know whether it's because of the VIP syndrome doing too much or whether he's started to show some signs that it's taking a toll on his body."

Remdesivir, sold by Gilead Sciences under the brand name Veklury, is an antiviral developed to treat Ebola that has been repurposed to treat COVID-19. Earlier this year, the U.S. Food and Drug Administration authorized its use in hospitalized patients, and although there have been shortages, the company now promises hospitals will have an ample supply.

Research shows the drug can shorten by several days the hospital stay of patients who are seriously ill, but not in intensive care.

Remdesivir is generally given in a five-day course, intravenously.

Dr. Brian Garibaldi, a pulmonary critical care doctor treating the president, said Saturday that Trump received his first dose Friday night and "our plan is to continue a five-day treatment course." It's not clear whether that means Trump will stay at Walter Reed until he finishes the treatment.

Conley said he tried the combination of the antibodies and remdesivir because the two work in different, complementary ways.

"We're maximizing all aspects of his care," Conley said, "attacking this virus in a multi-prong approach."

Several of the doctors interviewed by USA TODAY supported the decision to try both drugs, though they noted that they've never been studied in combination.

Experts were perplexed by the remainder of items on the medication list released Friday, which included vitamin D, zinc, the antacid Pepcid, melatoninand aspirin. It's not clear whether Trump continued taking these after being hospitalized.

For vitamin D, research has shown that people who have low levels of the vitamin in their bodies fare worse when they contract COVID-19, but bringing levels above normal appears to do nothing. It's not clear whether Trump has a deficit of vitamin D, which is produced during exposure to direct sunlight and is also found in some foods.

Data also suggestspatients with low levels of zinc in their blood fare worse with COVID-19 than those with normal levels. But again, there is no evidence that supplementing with zinc improves COVID-19 outcomes.

Researchers have suggested that melatonin, a natural sleep aid, may help reduce inflammation and therefore provide benefit to COVID-19 patients, though studies into its effectiveness are just beginning.

The antacid famotidine, sold over the counter as Pepcid, also has been discussed as a possible treatment for COVID-19. The heartburn medicine is generally considered safe, and there is some data suggesting a benefit, but the research did not meet a high standard, and the improvement seen could have happened just by chance, Massachusetts General's Gandhi said.

The Infectious Disease Society of America's treatment guidelines, which Gandhi helps write, recommends against using the medicine to treat COVID-19 outside of a clinical trial, "not because it has a lot of side effects it's an antacid, it's available over the counter it's just that there's not good evidence that it has a benefit," he said.

Aspirin is another head-scratcher, Prasad and others said.

It is not uncommon for people who have had heart attack or stroke to take a baby aspirin a day to prevent a repeat, but there is no evidence the president takes it for that purpose. Because aspirin can thin the blood, it is generally not given to reduce a fever, which Trump had on Friday.

Prasad said he's not sure why Trump would be given any one of these unproven therapies, no less the combination. "I have some question marks about why he's taking them," Prasad said. "They're not likely to be beneficial."

Contact Karen Weintraub at kweintraub@usatoday.com and Elizabeth Weise at eweise@usatoday.com

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

Read or Share this story: https://www.usatoday.com/story/news/health/2020/10/04/trump-medication-experimental-covid-treatments/3598232001/

Link:

Trump is receiving lots of medical care, and some doctors wonder if it's too much. - USA TODAY

3 new degrees approved, including Ph.D. in regenerative medicine – IU Newsroom

The Indiana University Board of Trustees has approved three new degrees, including a doctorate in the medical field and a master's in the accounting field.

During its meeting Oct. 1, the trustees supported three proposed degrees:

Regenerative medicine is a field that involves replacing or regenerating human cells, tissues or organs to establish, restore or enhance normal function.

The Ph.D. program in regenerative medicine and technologies will be offered by the Indiana Center for Regenerative Medicine and Engineering and the Department of Surgery at the IU School of Medicine. The program, open to practicing medical doctors, will provide an avenue for cutting-edge research that can be used in new ways to treat patients.

Before this approval, IU had no graduate-level programs for students seeking a degree in regenerative medicine and technologies. The labor market demand for such graduates is considered strong, with jobs in biotechnology companies, academic laboratories, and medical device manufacturing and logistics companies.

Changes in the accounting field and large employers' expressed needs have prompted the development of a new Master of Science in accounting curriculum that will prepare students for the emerging data-focused professional services workplace. With the proliferation of data and analytics techniques applications in the business world, integrated accounting, data and analytics competencies are required for the best job placements.

The new Master of Science in accounting with data and analytics degree will be offered by the Kelley School of Business. It will replace the current, traditional Master of Science in accounting degree as the residential offering on the Bloomington campus. The traditional Master of Science in accounting will continue to be offered through the Kelley School's online programs and will target "career switchers."

Students who seek the flexibility of an online format, have an interest in studying the foundations of sustainability and want to apply that knowledge to complex socio-environmental problems can find that opportunity in a new offering at IU Northwest, through the College of Arts and Sciences. The Bachelor of Arts in sustainability studies is a collaborative online degree, and was previously approved at IUPUI, IU East, IU Kokomo, IU South Bend and IU Southeast.

Regional demand for energy and sustainability specialists and the demand for "green" jobs are expected to grow over the next 10 years. Graduates with the degree could find jobs such as an energy analyst, environmental health and safety specialist, or an occupational health and safety technician.

The degrees approved by IU's trustees still await final approval by the Indiana Commission for Higher Education.

Originally posted here:

3 new degrees approved, including Ph.D. in regenerative medicine - IU Newsroom

Trump Has Treatment Options for Coronavirus. None of Them Are Good. – Foreign Policy

EDITORS NOTE: Were making some of our coronavirus pandemic coverage free for nonsubscribers. You can read those articles here and subscribe to our newsletters here.EDITORS NOTE: Were making some of our coronavirus pandemic coverage free for nonsubscribers. You can read those articles here and subscribe to our newsletters here.

President Donald Trump and first lady Melania Trump are infected with the SARS-CoV-2 virus that causes the dangerous disease COVID-19. Some of the presidents staff and individuals he has met recently have also tested positive for the virus, and results on a long list of White House and campaign staff are pending. Trump was taken to Walter Reed Military Medical Center Friday afternoon, where he will remain, White House officials say, for a few days. But what awaits himand the country he still leadsas he deals with this virus?

Despite his 74 years and overweight frame, Trump has always tried to portray himself as vigorous, healthy, and even athletic. While depicting his thinner 77-year-old opponent Joe Biden as doddering, slow, and senile, Trump has tried to give the impression that he is Bidens junior by far, more than the three chronological years that separate them.

He has similarly, and repeatedly, depicted the COVID-19 risk as somebody elses problem. Older people with heart conditions might have to be concernedcertainly not Trump.

On Sept. 21, Trump looked out over a mostly mask-free crowd in Swanton, Ohio, and beamed, Wow, this is a big crowd. This is a big crowd. The crowd roared. And Trump brushed off concern about masks and COVID-19, saying: It affects elderly people. Elderly people with heart problems. If they have other problems, thats what it really affects. Thats it. But it affects virtually nobody. Its an amazing thing.

The federal government defines seniors and elderly, for most medical, retirement, and tax purposes, as individuals over 65 years of age, which clearly puts Trump in the category he dismissed in Swanton as virtually nobody. Does he suffer from any underlying conditions, other than his weight, that may put him at additional risk? We dont really know, because in his constant struggle to appear youthful, covering up his thinning hair and playing record-breaking hours of presidential golf, Trump has made sure that no genuine medical work-up reaches the public.

His Manhattan physician, Harold Bornsteina wild-haired, colorful figure who looks more like a hippie than a board-certified gastroenterologistin August 2016 certified, His health is excellent, especially his mental health.And in a December 2015 statement he said was dictated to him by a Trump aide and written hastily while a limousine waited outside, he wrote that then-candidate Trumps physical strength and stamina were extraordinary.

Former White House physician Ronny Jackson, who is now the Republican Partys candidate for the 13th Congressional District in Texas, has benefited tremendously since coming to the presidents attention in 2017. White House staff and Trump campaign officials have raised funds for his shot at a congressional seat and advised his campaign. Back in January 2018, Jackson, then a U.S. Navy rear admiral, conducted the first and only official medical examination of the president at Walter Reed National Military Medical Center. In a press conference following Trumps checkup, Jackson said his patient had incredible genes, performed beautifully on a cognitive test, and claimed that if he had adhered to a better diet over the past 20 years, he could have lived to be 200, according to the New York Times. Shortly after that, Trump nominated Jackson to head the Department of Veterans Affairsa move that was foiled by allegations that the Navy doctor had handed out medicines to officers without medical indications.

Over the years, Trump and his staff have let slip tidbits of his real health status. He reportedly takes Propecia to fight hair loss, daily aspirin to prevent heart attacks, the cholesterol-lowering statin Crestor, and regular doses of the antibiotic tetracycline to deal with the colorful rosacea blotches that occasionally appear on his cheeks. According to the White House physicians office, Trump is also taking supplements of zinc, vitamin D, melatonin to combat insomnia, and the histamine-blocker famotidine. None of this is particularly remarkable for an older, overweight American manexcept that Trump goes to great lengths to not be labeled as such.

This year, concerns have been raised about incidents of Trumps slurred speech and apparent trouble walking. In June, the president had obvious difficulty descending a ramp following a speech to West Point cadets. During the speech, he struggled to hold and drink from a glass of water. In a June 14 tweet, Trump said the ramp was very slippery, and in a subsequent speech, with much fanfare, he showed a cheering crowd that he was able to hold a glass of water with one hand.

Eleven months ago (Nov 2019) President Trump made a surprise, unscheduled visit to Walter Reeds hospital, where he remained for two days. Trumps doctor, Sean Conley, declined to reveal the reason for the two-day medical visit, though he pointedly dismissed the President underwent tests for cardiac or neurologicconditions.

In November 2019, an anonymous alleged White House staffer wrote in a book titled A Warning: I am not qualified to diagnose the presidents mental acuity. All I can tell you is that normal people who spend any time with Donald Trump are uncomfortable by what they witness. He stumbles, slurs, gets confused, is easily irritated, and has trouble synthesizing information, not occasionally but with regularity. Those who would claim otherwise are lying to themselves or to the country.

Combined, these pieces of evidence suggest that Trump may have some of the underlying health conditions that put COVID-19 patients at risk for severe outcomes.

If current reports are accurate and the president has already displayed symptoms of fatigue and breathing difficulties, he may soon become too ill to do his job, as was the case with British Prime Minister Boris Johnson. As one of my friends put it while she struggled at home with the virus, It feels like an elephant is sitting on my chest. In the coming days, the severity of Trumps illness will become more apparent, including whetherlike Johnsonhe requires respiratory support.

More worrying, from the point of view of Trumps role as commander in chief, is increasing evidence that SARS-CoV-2 can infect the brain and cause cognitive dysfunctions, including hallucinations, severe headaches, dizziness, and impaired judgment. The list of neurological symptoms connected with COVID-19 is very long, including confusion, delirium, senility, and permanent brain damage. These, and other brain-associated symptoms, may persist for months.

Assuming the president is willing to undergo state-of-the-art treatmentforgoing the hydroxychloroquine, forsythia, bleach, and other alleged treatments he has in the past espousedhe may ask Anthony Fauci and his staff at the National Institute of Allergy and Infectious Diseases to consult on his case. Based on the latest scientific findings, they might urge a blood test to determine whether Trump is part of a genetic minority14 percent of severe COVID-19 caseswhose DNA programs antibodies that attack type I interferons, molecules now known to be crucial to the bodys ability to fight off the virus.

According to the White House, the President was transported to Walter Reed Friday afternoon, and underwent an infusion treatment with monoclonal antibodies, made by Regeneron a targeted immunological treatment that has not yet been approved by the FDA.

If he wishes to take advantage of the U.S. Food and Drug Administrations emergency use authorization for convalescent plasma therapy, receiving possibly beneficial blood products from COVID-19 survivors, he should start that treatment immediately, as clinical evidence points to whatever benefits it may provide as occurring in the earliest stages of the disease. Given his alleged cholesterol issues and the possibility that slurred speech and walking/balance issues are related to an underlying heart condition, Trumps physicians should pay close attention to his cardiac performance. There is increasing evidence that SARS-CoV-2 directly attacks and destroys heart muscle cells and causes longer-term heart problems and blood clotting throughout the body, even in people who had apparently asymptomatic infections. Another controversial treatment, the Ebola drug remdesivir, may help stave off severe outcomesbut like plasma therapy, its benefits are greatest if taken immediately. Physicians in the United Kingdom routinely now give a cheap steroid, dexamethasone, to COVID-19 patients to control dangerous overreactions against the virus on the part of patients immune systems. And, of course, Fauci or any other qualified physician would advise the president to get more sleep than usual and remain in bed.

Given the great lengths Trump has gone to appear younger than his true 74 years and hide his medical history from public scrutiny, it is difficult to predict how his body will manage the virus. From a public health point of view, he clearly must remain in strict quarantine for a minimum of two weeks after he is symptom-free, in order to protect others from his contagion. Medically, he may prove that, as he said months ago, its just like the flu, recovering in a few days. But given what is known about his health, weight, and age, Trump may face a tough battle with the coronavirus.

At a minimum, both for his personal health and the safety of others, Trump can no longer hold mass campaign rallies. The scheduled Oct. 15 debate against Biden, planned for Miami, should be canceled. The Oct. 22 Nashville debate may also need to be reconsidered, possibly moved to a virtual format. Vice President Mike Pences schedule should be reassessed, keeping him close to the White House, where, should the presidents condition worsen significantly, he may be called on to assume Oval Office duties.

Someone introduced the virus into the White House circle, possibly exhibiting a failure to quarantine, wear masks and practice social distancing. Its worth noting that in addition to the President and First Lady, four people who attended the small, mostly mask-free September 26 ceremony in the White House Rose Garden have tested positive. All were seated in the front three rows at the gathering, during which Judge Amy Coney Barrett was formally nominated to serve on the U.S. Supreme Court. In addition, three reporters who covered the event today tested positive, bringing the total to nine people, linked to a small, tightly-knit assemblage.

While many commentators and internet afficionados have greeted news of the president and first ladys illness with sarcasm and smirks about Trump shunning masks and downplaying the COVID-19 crisis, this disease has created a time of reckoning for the nation. There is nothing amusing or sarcasm-inviting about an ailing president of the United States, especially when he is a man of high-risk health facing a viral enemy as serious as SARS-CoV-2.

Read the original post:

Trump Has Treatment Options for Coronavirus. None of Them Are Good. - Foreign Policy

SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy – MIT News

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRFs initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.

SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.

Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART. In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society, says Krystyn Van Vliet, co-lead principal investigator at SMART CAMP, professor of materials science and engineering, and associate provost at MIT.

Understanding glaucoma progression for better-targeted treatments

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, MIT, and National University of Singapore (NUS). The team will seek to establish first principles-founded and statistically confident models of glaucoma progression in patients. Through retinal biomechanics, the models will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better-targeted treatments.

Glaucoma, an eye condition often caused by stress-induced damage over time at the optic nerve head, accounts for 5.1 million of the estimated 38 million blind in the world and 40 percent of blindness in Singapore. Currently, health practitioners face challenges forecasting glaucoma progression and its treatment strategies due to the lack of research and technology that accurately establish the relationship between its properties, such as the elasticity of the retina and optic nerve heads, blood flow, intraocular pressure and, ultimately, damage to the optic nerve head.

The research is co-led by George Barbastathis, principal investigator at SMART CAMP and professor of mechanical engineering at MIT, and Aung Tin, executive director at SERI and professor at the Department of Ophthalmology at NUS. The team includes CAMP principal investigators Nicholas Fang, also a professor of mechanical engineering at MIT; Lisa Tucker-Kellogg, assistant professor with the Cancer and Stem Biology program at Duke-NUS; and Hanry Yu, professor of physiology with the Yong Loo Lin School of Medicine, NUS and CAMPs co-lead principal investigator.

We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction, says Barbastathis.

Cell transplantation to treat irreparable spinal cord injury

Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), the second research project, gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), the University of Cambridge, and MIT. The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project, an intersection of engineering and health, will achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimized engineering methods to prepare cells and biomaterials for treatment.

Spinal cord injury (SCI), affecting between 250,000 and 500,000 people yearly, is expected to incur higher societal costs as compared to other common conditions such as dementia, multiple sclerosis, and cerebral palsy. SCI can lead to temporary or permanent changes in spinal cord function, including numbness or paralysis. Currently, even with the best possible treatment, the injury generally results in some incurable impairment.

The research is co-led by Chew Sing Yian, principal investigator at SMART CAMP and associate professor of the School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at NTU, and Laurent David, professor at University of Lyon (France) and leader of the Polymers for Life Sciences group at CNRS Polymer Engineering Laboratory. The team includes CAMP principal investigators Ai Ye from Singapore University of Technology and Design; Jongyoon Han and Zhao Xuanhe, both professors at MIT; as well as Shi-Yan Ng and Jonathan Loh from Institute of Molecular and Cell Biology, A*STAR.

Chew says, Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many. Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the health-care industry and society, says Hanry Yu, co-lead principal investigator at SMART CAMP, professor of physiology with the Yong Loo Lin School of Medicine, NUS, and group leader of the Institute of Bioengineering and Nanotechnology at A*STAR.

The grants for both projects will commence on Oct. 1, with RAMP expected to run until Sept. 30, 2022, and ScaNCellS expected to run until Sept. 30, 2023.

SMART was. established by the MIT in partnership with the NRF in 2007. SMART is the first entity in the CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five interdisciplinary research groups (IRGs): Antimicrobial Resistance, CAMP, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

CAMP is a SMART IRG launched in June 2019. It focuses on better ways to produce living cells as medicine, or cellular therapies, to provide more patients access to promising and approved therapies. The investigators at CAMP address two key bottlenecks facing the production of a range of potential cell therapies: critical quality attributes (CQA) and process analytic technologies (PAT). Leveraging deep collaborations within Singapore and MIT in the United States, CAMP invents and demonstrates CQA/PAT capabilities from stem to immune cells. Its work addresses ailments ranging from cancer to tissue degeneration, targeting adherent and suspended cells, with and without genetic engineering.

CAMP is the R&D core of a comprehensive national effort on cell therapy manufacturing in Singapore.

Link:

SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy - MIT News

Your Column Here – Kindness is the Best Medicine – – Santa Monica Daily Press

As a frontline healthcare worker, Jean Abac is committed to overcoming any fear and doing her part in the fight against the COVID-19 pandemic. She has been working seven days a week as a nurse at three area hospitals.

Supporting patients needs is especially meaningful for her because she knows that there is now a nursing shortage and those on the job can be concerned even reluctant about providing care, particularly at the bedside, to those diagnosed with coronavirus.

Right now is the time to help, says Jean, who splits her work hours among the UCLA Medical Center in Santa Monica, Olympia Medical Center and West Hills Hospital. Nurses have a huge responsibility. We signed up to be in this position. This is our job and that holds a lot of importance. You take an oath to be a part of a greater good.

Jean, 29, a resident of the Palms area of Los Angeles, emigrated from the Philippines as a teen and benefited from being selected as a United Health Foundation Diverse Scholar. The program, an initiative to promote diversity in the health care industry that was created and is funded by the United Health Foundation, will help pay for her continuing education to become a nurse practitioner.

The nursing profession is a family affair. Her fianc, Spencer, is also a nurse and he is working six days a week. They keep each other motivated. Were just trying to do our best to make the most of whats currently happening, says Jean, whose biological father is also a nurse in a nursing home. Her mother previously worked overnight shifts as an in-home caregiver.

Over the past nine years that Jean has been a nurse, she has learned to become a more effective health care provider by making, what she calls, cultural connections. She strives to be empathetic with all the patients she serves. Shes quick to acknowledge their ethnic or racial backgrounds (such as conversing in Tagalog with fellow Filipinos) and create a general sense of familiarity and acceptance. She has also learned a handful of key words in Spanish that she says work like magic in making a difference with Latinos and helping them cope with issues of vulnerability.

In my daily interactions with my patients, I try to really get to know them on a personal level, and especially learn what makes them laugh, she says. When in the hospital, theres just way too many things that scare people, especially the big unknowns like waiting for their diagnosis or what will be the prognosis once they start their treatments.

The trauma that comes with a sickness and diagnosis is one that Jean knows firsthand. During nursing school, she was treated for a serious condition that could have led to cervical cancer. And now, as the deadly COVID-19 pandemic continues, there is the constant threat of exposure.

There are a lot of worries among me and my co-workers. Some get sick and then you worry if you will get sick and that youll bring it home to your loved ones, she says, referring to COVID-19. But we all signed up to help every patient with every kind of disease.

Jeans award as a Diverse Scholar will help her continue to develop and grow in her career. She wants to be a role model for younger generations and help recruit others into nursing. Shes trying to emulate the professional mentors who played such a big role for her when she first became a nurse.

Its very humbling, she says. I feel such great purpose knowing that I was part of allowing patients to receive a second, third or however many chances theyve been granted again in life. Were only here for a short time and knowing that you were part of lengthening somebodys life a little longer so that they can share more laughs, loves and memories with other people is an unexplainable feeling.

More here:

Your Column Here - Kindness is the Best Medicine - - Santa Monica Daily Press

Trastuzumab-Containing Regimens and Novel Drugs Mark the Precision Medicine Era of HER2-Positive Breast Cancer – Targeted Oncology

The aggressiveness of early breast cancer and the overall prognosis of patients with the disease is highly dependent on the presence of aberrations in the tumor. HER2 overexpression, in particular, is found in 10% to 40% of breast tumors, which make tumors with these characteristics less responsive to the hormone therapy and cytotoxic agents most commonly used for the treatment of breast cancer.1

Although HER2 positivity has been identified as a predictive factor of response to chemotherapy, it remains controversial considering that responses to chemotherapy can vary in patients with certain disease characteristics. Once trastuzumab (Herceptin), the first targeted therapy for HER2-positive breast cancer entered the paradigm, it was clear that patients had more options,1,2 but, experts were unaware of how far targeted therapies could go in terms of improving outcomes.

Treatment should be individualized based on the patients presenting characteristics, including tumor size, lymph node status, and hormone receptor status, Kari B. Wisinski, MD, medical oncologist, UW Health and the University of Wisconsin Carbone Cancer Center, told Targeted Oncology, in an interview.

Individualizing therapy for our patients with HER2-positive disease can help us improve outcomes and decrease toxicity for our patients, added Sara Tolaney MD, MPH, associate director, Susan F. Smith Center for Women's Cancers, director, Clinical Trials, Breast Oncology, and senior physician, at the Dana-Farber Cancer Institute, and assistant professor of medicine, at Harvard Medical School.

Before the Agent Boom in HER2-Positive Breast Cancer

As a newly introduced targeted therapy in the field of HER2-positive breast cancer in 1998, trastuzumab added to cytotoxic chemotherapy demonstrated a significant improvement in disease-free survival (DFS) in patients with HER2-positive breast cancer, according to results from the N9831 trial (NCT00005970). The result was a 10-year DFS rate of 73.7% with the addition of trastuzumab compared with 62.2% with chemotherapy alone (HR, 0.60; 95% CI, 0.53-0.78) and the 10-year OS rate achieved was 84% versus 75.2% (HR, 0.63; 95% CI, 0.54-0.73).3

As scientific advances were made, trastuzumab continued to be used with chemotherapy, but novel targeted therapies also emerged in the landscape.2

The Thriving Targeted Therapy Research in HER2-Positive Breast Cancer

Many targeted therapies are now FDA approved as treatment of patients with early HER2-positive breast cancer and, unsurprisingly, many of the regimens used in clinical trials for these patients include trastuzumab or are intended to be administered after trastuzumab treatment is completed.

Several new targeted therapies have emerged in the last several years for HER2-positive breast cancer. First of all, we have pertuzumab [Perjeta], the anti-HER2 monoclonal antibody, which has been supported in the neoadjuvant setting as well as in the adjuvant setting. There is neratinib [Nerlynx], which is an oral tyrosine kinase inhibitor that is now approved as an extended duration anti-HER2 treatment following completion of 1 year of trastuzumab in the adjuvant setting, Wisinski explained.Lastly, we have recent data for T-DM1 [trastuzumab emtansine; Kadcyla], which is now FDA approved in the post-neoadjuvant setting in patients with residual disease after standard upfront chemotherapy and anti-HER2 directed therapy. Each of these 3 medications has significantly changed our landscape.

One of the most revolutionary clinical trials exploring the use of novel targeted therapies in patients with breast cancer is the I-SPY-2 platform trial, which includes a subset of patients with HER2-positive disease. I-SPY-2 is a series of mini studies of novel drugs combined with chemotherapy compared with single-agent standard of care, which is the combination of paclitaxel plus trastuzumab followed by doxorubicin and cyclophosphamide. The trial includes 4000 patients.

The combination treatment arms being explored in I-SPY-2 include AMG 386 with or without trastuzumab, AMG 479 (Ganitumab) plus metformin, MK-2206 with or without trastuzumab, T-DM1 plus pertuzumab, pertuzumab plus trastuzumab, talazoparib (Talzenna) plus irinotecan, patritumab plus trastuzumab, durvalumab (Imfinzi) plus olaparib (Lynparza), and cemiplimab (Libtayo) plus durvalumab plus olaparib. The monotherapy arms include ganetespib, ABT-888, neratinib, PLX3397, pembrolizumab (Keytruda), SGN-LIV1A, tucatinib (Tukysa), and cemiplimab, in all breast cancers.4

Aside from the I-SPY-2 trial, vaccine therapies including the HER2-sensitized dendritic

cell vaccine (NCT0338755), the dendritic cell vaccine compared to the WOKVAC vaccine (NCT03384914), and TPIV100, another HER2 vaccine (NCT04197687) are under investigation in phase 1/2 clinical trials.

There have also been studies of combination chemotherapy like trastuzumab plus chemotherapy (NCT03894007), which is a phase 2 study evaluating treatment before surgery in patients with HER2-amplified early breast cancer. Therapeutic strategies that are even further along in the pipeline are immune checkpoint inhibitor monotherapy and immunotherapy and chemotherapy combination that first demonstrated efficacy in other diseases.

The immunotherapy agents and combinations currently under investigation for early HER2-positive breast cancer include the phase 2, open-label, randomized, multicenter trial of paclitaxel plus pembrolizumab versus pembrolizumab alone (NCT03747120); the phase 2 trial of doxorubicin, cyclophosphamide, and paclitaxel plus nivolumab (Opdivo; NCT03742986) in inflammatory breast cancer, which includes patients with HER2-positive disease in 1 arm who will be treated with added trastuzumab and pertuzumab; as well as the single-arm, open-label study of M7824 ahead of standard neoadjuvant therapy (NCT03620201), which is evaluating patients with stage II or III HER2-positive breast cancer.

Expanding the Possibilities of Trastuzumab

Trastuzumab is considered a standard chemotherapy backbone in the landscape of HER2-positive breast cancer.1 To keep the efficacy going, Wiscinski suggests using trastuzumab not only to escalate but also to de-escalate treatment.

One of the strategies that still needs to be considered is not just escalating treatment with these newer agents, but also the idea of deescalating for smaller HER2-positive breast cancer. In particular, I am thinking about either the regimen of paclitaxel with trastuzumab or T-DM1 as a single-agent, Wiscinski stated. Overall, the escalation treatment strategy is sometimes appropriate, but other times, de-escalation is a critical thing for treating HER2-positive breast cancer.

Tolaney also noted, during an interview, that de-escalation plays a critical role in how patients with HER2-positive breast cancer are treated.

By tailoring adjuvant therapy based on response to preoperative therapy, we are able to escalate therapy for patients with residual disease, and de-escalate for patients with pathologic complete response, Tolaney stated.

The de-escalation strategy is an area of active research as well. Currently, the CompassHER2-pCR study (NCT04266249), the PALTAN study (NCT02907918), and the TOUCH trial (NCT03644186) are all investigating de-escalation of trastuzumab-containing regimens.

Wiscinski noted, however, that challenges do exist with this strategy and should be explored future.

An unmet need is having better predictors of who needs an escalation treatment and who can have their treatment de-escalated. For example, right now we rely a lot on nodal status and tumor size, but there could potentially be genomic markers or diagnostic tests that could help us identify which patients have very HER2-sensitive disease and potentially could be treated with less chemotherapy, she explained.

References:

1. Kurebayashi J. Biological and clinical significance of her2 overexpression in Breast Cancer. Breast Cancer. 2001;8(1):45-51. doi:10.1007/BF02967477

2. Sharifi M, Wisinski KB. Advances in the treatment of early-stage her2-positive breast cancer. Clin Adv Hematol Oncol. 2020;18(8):482-492.

3. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730

4. The I-SPY 2 Trial. I-SPY2 website. Accessed October 2, 2020. https://bit.ly/36qn2Kk

View post:

Trastuzumab-Containing Regimens and Novel Drugs Mark the Precision Medicine Era of HER2-Positive Breast Cancer - Targeted Oncology

Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic…

Aimed at offering Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) report readers with updated information as well as market relevant cues to leverage uninhibited growth in the Global Regenerative Medicine market, this intricately researched, designed, and articulated real-time reference of the market is a culmination of in-depth research mettle and best in class primary and secondary research initiatives that collectively influence a favorable growth trajectory in the Global Regenerative Medicine market.

In continuation with all the above market specific information furnished above, the report further in its subsequent sections also throws light upon other additional yet pertinent details that further channelize revenue generation in the Global Regenerative Medicine market. The report highlights massively the core growth propellants such as market driving factors, prevailing challenges and the like that tend to have a negative growth impact on the global Global Regenerative Medicine market.

Request a sample of Global Regenerative Medicine Market report @ https://www.orbisresearch.com/contacts/request-sample/4707408

Key Manufacturers Analysis:

Novartis AGMedtronic PlcBristol Myers Squibb (Celgene Corporation)Smith+Nephew (Osiris Therapeutics, Inc.)

Global Regenerative Medicine market Segmentation by Type:

Type IType IIType III

Global Regenerative Medicine market Segmentation by Application:

Application IApplication IIApplication III

Access full report @ https://www.orbisresearch.com/reports/index/global-regenerative-medicine-market-size-and-forecast-with-impact-analysis-of-covid-19-2020-2024

Various other dynamics of the Global Regenerative Medicine market pertaining to the growth prospects have been mentioned and well elaborated in the course of the report documentation thus ushering a novel perspective for the players to instrument growth propelling business decisions, defying stringent competition in the Global Regenerative Medicine market. Based on a thorough analytical review leading players comprising both established and new market aspirants in the Global Regenerative Medicine market can have a thorough understanding about the market and subsequently chalk out elaborate plans to steer remunerative returns in the aforementioned Global Regenerative Medicine market.

Key Regions:

North AmericaEuropeAsia PacificROW

All the mentioned updates about the Global Regenerative Medicine market specified in the report have been derived post a dedicated research initiative comprising primary and secondary research practices. Proceeding into unraveling new developments in the report pertaining to the Global Regenerative Medicine market, the report is committed to offer a decisive, problem solving approach based on which readers are encouraged to unravel the various discerning factors and inputs that collectively orchestrate an optimistic growth trail in the discussed Global Regenerative Medicine market.

Ready-to refer Market Insider Reports: Top Reason to Buy the Report

1. A team of expert research veterans, practicing best in industry roles to derive real time developments in the Global Regenerative Medicine market, affecting growth.2. Systematic segment-wise analysis to identify growth reckoning segment.3. A thorough historical study to decode future growth trajectory.4. Rear view analysis of opportunity landscape and barrier analysis and threat identification.5. Astute analysis of the competition spectrum to identify market leaders and their growth favoring business tactics.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4707408

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

The rest is here:

Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic...

Need an excuse to clean out your medicine cabinet? Here it is – WYDaily

Police departments have been participating in the national Drug Take Back event since 2010 to collect extra and unused prescription medications. (WYDaily file/Courtesy Williamsburg Police Department)

If youre looking to clean out your medicine cabinet, then October is the perfect time to do it.

The York-Poquoson Sheriffs Office, James City County Police and the Williamsburg Police Department are each hosting Drug Take Back events on Oct. 24 from 10 a.m.- 2 p.m.

The event is a Drug Enforcement Administration regulated event.

Too often, unused prescription drugs find their way into the wrong hands. Thats dangerous and often tragic, Shelley Ward, spokeswoman for YPSO, wrote in an email.

Thats why its great to see hundreds of folks from across our area safely and anonymously clean out their medicine cabinets, Ward added.

In a non-COVID year, local law enforcement agencies typically hold events like this twice a year. But Williamsburg Police Officer Aundrea Holiday said the department had to cancel their April Drug Take Back.

Statistics show when you leave the unused medication around, then it gets into the hands it shouldnt be, whether it be teenagers or young kids, Holiday said. We can go ahead and destroy it safely. Its a win-win for the community.

She added flushing prescription medication and other drugs is not an effective nor safe way to dispose of these items because it gets in the waterways.

All locations are accepting prescription solid dosage medications, including tablets and capsules. Intravenous solutions, liquid medications, over-the-counter medications, injectables and needles will not be accepted, nor will illicit substances, including marijuana and methamphetamines. E-cigarettes and vaping devices will only be accepted if the batteries have been removed.

Williamsburg Police collaborated with the Williamsburg Fire Department across the street so they are allowed to accept over the counter medications and sharps, such as needles, at their location.

The James City County Police Department will have their drug take back at the county Law Enforcement Center on 4600 Opportunity Way.

Williamsburg Police is having their event at the Williamsburg Fire Department on 440 N Boundary St. There will be a drop box outside so people can remain in their vehicles when dropping off medication.

The YPSO will have their Drug Take Back at the Department of Public Works on 105 Service Drive. In an effort to keep people safe, deputies will go vehicle to vehicle with a container to collect medications.

YOU MIGHT ALSO WANT TO CHECK OUT THESE STORIES:

Always be informed. Click here to get the latest news and information delivered to your inbox

Go here to read the rest:

Need an excuse to clean out your medicine cabinet? Here it is - WYDaily

Palliative medicine and dying with dignity – The Irish Times

Sir, As individuals and members of the Irish Palliative Medicine Consultants Association (IPMCA), we are gravely concerned by any proposal to legislate for assisted suicide and euthanasia in Ireland.

Based on our collective experience over many decades of providing specialist care to thousands of individuals in Ireland and their families each year, we have closely observed the experiences of people who have lived and are living with serious illness.

The threats of the proposed Bill to healthcare in Ireland, to the true meaning of the doctor-patient relationship and to the future of what we know compassionate and supportive specialist palliative care to be are many. We worry about the impact on people who already struggle to have their voices heard in our society older adults, the disabled, those with mental illness and others. We worry that the most vulnerable are those who may be made to feel a burden to their families and come under pressure to end their lives prematurely.

Our experiences tell us that many in our society dont really know what dying is like, or how rare it is that severe pain cannot be controlled. Most people do not see that within the easing of physical, psychological or spiritual distress and addressing peoples fears, hopes, sadness and loss, the goal of palliative care remains to enhance the living of each life which often transforms the experiences of living, dying and bereavement for individual patients and their families.

We are convinced that as dying with dignity is already present within healthcare in Ireland, no change to our current laws is required. Yours, etc,

FEARGAL TWOMEY,

Consultant Physician

in Palliative Medicine,

Limerick and

Chairman of the Irish

Palliative Medicine

Consultants Association;

Prof TONY OBRIEN,

Clinical Professor

of Palliative Medicine,

University College Cork;

Dr MARIE TWOMEY,

Consultant in Palliative

Medicine,

St Lukes Hospital,

Dublin 6;

Dr NORMA OLEARY,

Consultant Physician

in Palliative Medicine,

Our Ladys Hospice

and Care Services and

St Jamess Hospital,

Dublin 8,

Dr VAL OREILLY,

Consultant in Palliative

Medicine,

Limerick;

Prof KAREN RYAN,

UCD Clinical Professor,

Consultant in Palliative

Medicine;

Dr DENISE HAYES,

Consultant in Palliative

Medicine,

University Hospital

Waterford;

FAITH CRANFIELD,

Consultant in Palliative

Medicine,

St Francis Hospice

Blanchardstown and

Connolly Hospital,

Dublin 15;

MARIAN CONROY,

Consultant Physician in Palliative Medicine,

UL Hospitals Group and

Milford Care Centre, Limerick;

Dr MAGS CLIFFORD,

Consultant in Palliative Medicine

Cork Kerry Community Healthcare,

Kerry Specialist

Palliative Care Services,

University Hospital Kerry;

Dr CATHRYN BOGAN,

Consultant in Palliative Medicine

North West Hospice,

Sligo University Hospital;

Dr AISLING OGORMAN,

Consultant Physician

in Palliative Medicine,

Honorary Clinical Senior Lecturer,

Royal College of Surgeons in Ireland,

Louth & Meath Specialist Palliative

Care Services,

Dchas Centre,

Our Lady of Lourdes Hospital,

Drogheda;

Dr CLARE MCALEER,

Consultant in Palliative Medicine ,

Beaumont Hospital,

and St Francis Hospice, Raheny;

Dr BARBARA

SHEEHY-SKEFFINGTON,

Locum Consultant

in Palliative Medicine,

Our Ladys Hospice and Care Services,

and St Jamess Hospital, Dublin;

Dr. BERNADETTE BRADY,

Consultant in Palliative Medicine,

Tallaght University Hospital;

Dr EILEEN MANNION,

Clinical Lecturer

in Palliative Medicine, NUIG,

Consultant in Palliative Medicine,

Galway University Hospital and Roscommon,

Clinical Lecturer in Palliative Medicine, NUIG,

Consultant in Palliative Medicine,

Galway University Hospital

& Portiuncula University Hospitals;

DR MAEVE OREILLY,

Consultant in Palliative Medicine,

St Lukes Hospital, Dublin,

Locum Consultant in Palliative Medicine,

UL Hospitals Group

and Milford Care Centre, Limerick.

See original here:

Palliative medicine and dying with dignity - The Irish Times

Chicken soup really is the best medicine – Euro Weekly News

CHICKEN soup has been known and loved throughout the world for centuries. a little research shows this dish may have its origins in ancient Greece or perhaps in China (the Chinese being the first to think of adding noodles), but that it is also practically synonymous with traditional Jewish cooking.

Besides being tasty and comforting, chicken soup is also known for the curative properties that have earned it the nickname of Jewish penicillin. And chicken soups health benefits arent just another folktale told to get you to clean your plate (or rather, bowl).

Science Daily says that researchers from the Pulmonary and Critical Care Medicine Section of the Nebraska Medical Center studied how chicken soup interacted with blood samples and found that it did seem to have an anti-inflammatory effect that could possibly work to inhibit respiratory problems.

While researchers couldnt determine exactly what ingredient in the chicken soup was working to reduce inflammation, clinical dietitian Sandy Allonen gives her take on just how chicken soup works its magic.

She calls its clear broth warm and soothing, something that makes it a great source of hydration while youre sick, especially if you have a sore throat. She also notes that even the salt, as well as the other seasonings, can help combat the feeling of dull taste buds, while the veggies have vitamins and minerals that can help build a healthy immune system to fight off viruses and helpyour body recover from illness more quickly.

The carbs in the noodles will help fill you up, satisfy, and re-energize you, while the chicken is not only packed with immune-boosting protein as well as vitamins and minerals of its own but also contains high levels of tryptophan, a substance that Allonen says helps your body produce serotonin that can enhance your mood. Even the steam can help, if you serve your soup piping hot, by opening up airways, making it easier to breathe and producing a mild anti-inflammatory effect that can help relax your muscles and soothe the discomforts of cold symptoms.

Whether you make homemade chicken soup or open up a can, better stock up before cold and flu season hits. It may not be a miracle cure, but chicken soup really is the best medicine.

We hope you enjoyed this article Chicken soup really is the best medicine..

Euro Weekly News is delighted to continue to be able to bring you a range of News that doesnt cost you anything but your internet connection. Whether its Local Spanish News or International Entertainment News, weve got you covered!

View post:

Chicken soup really is the best medicine - Euro Weekly News